Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.89 [0.69, 1.15] | | < 1 | | 0% | 1 study (1/-) | 81.2 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 0.78 [0.54, 1.13] | | < 1 | | 0% | 1 study (1/-) | 90.5 % | NA | not evaluable | | important | - |
DCR | 2.79 [1.83, 4.24] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 3.46 [1.39, 8.64] | | > 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
TRAE (grade 3-4) | 1.66 [1.08, 2.57] | | < 1 | | 0% | 1 study (1/-) | 1.1 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.48 [0.02, 14.54] | | < 1 | | 0% | 1 study (1/-) | 65.9 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 0.58 [0.23, 1.44] | | < 1 | | 0% | 1 study (1/-) | 88.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.97 [0.06, 15.67] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Acute kidney injury TRAE (grade 3-4) | 0.97 [0.02, 49.28] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 1.95 [0.07, 58.51] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.64 [0.22, 1.83] | | < 1 | | 0% | 1 study (1/-) | 79.9 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 3.96 [0.44, 35.74] | | < 1 | | 0% | 1 study (1/-) | 11.2 % | NA | not evaluable | | non important | - |
Blood creatinine increased TRAE (grade 3-4) | 0.97 [0.02, 49.28] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 1.95 [0.07, 58.51] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.97 [0.02, 49.28] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 1.95 [0.07, 58.51] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 1.95 [0.07, 58.51] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
Dry skin TRAE (grade 3-4) | 0.48 [0.02, 14.54] | | < 1 | | 0% | 1 study (1/-) | 65.9 % | NA | not evaluable | | non important | - |
Dyspnoea TRAE (grade 3-4) | 0.97 [0.02, 49.28] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 3.37 [0.91, 12.46] | | < 1 | | 0% | 1 study (1/-) | 3.5 % | NA | not evaluable | | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.32 [0.03, 3.11] | | < 1 | | 0% | 1 study (1/-) | 83.5 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 0.97 [0.02, 49.28] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Hypersensitivity TRAE (grade 3-4) | 1.95 [0.07, 58.51] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
Hypertension TRAE (grade 3-4) | 1.95 [0.07, 58.51] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.97 [0.02, 49.28] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 0.97 [0.02, 49.28] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 3.92 [0.18, 87.59] | | < 1 | | 0% | 1 study (1/-) | 19.7 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 3.92 [0.18, 87.59] | | < 1 | | 0% | 1 study (1/-) | 19.7 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.97 [0.06, 15.67] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.32 [0.03, 3.11] | | < 1 | | 0% | 1 study (1/-) | 83.5 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 4.97 [0.57, 42.99] | | < 1 | | 0% | 1 study (1/-) | 7.4 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.97 [0.19, 4.88] | | < 1 | | 0% | 1 study (1/-) | 51.4 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 2.95 [0.30, 28.63] | | < 1 | | 0% | 1 study (1/-) | 17.7 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.97 [0.38, 2.51] | | < 1 | | 0% | 1 study (1/-) | 52.4 % | NA | not evaluable | | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 2.05 [0.89, 4.69] | | < 1 | | 0% | 1 study (1/-) | 4.5 % | NA | not evaluable | | non important | - |
Pancytopenia TRAE (grade 3-4) | 0.24 [0.01, 5.38] | | < 1 | | 0% | 1 study (1/-) | 81.2 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 1.95 [0.07, 58.51] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
Peripheral oedema TRAE (grade 3-4) | 1.95 [0.07, 58.51] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
Pneumonia TRAE (grade 3-4) | 1.95 [0.07, 58.51] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 0.48 [0.02, 14.54] | | < 1 | | 0% | 1 study (1/-) | 65.9 % | NA | not evaluable | | non important | - |
Pruritic rash TRAE (grade 3-4) | 1.95 [0.07, 58.51] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.97 [0.02, 49.28] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.97 [0.02, 49.28] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 3.73 [1.02, 13.61] | | < 1 | | 0% | 1 study (1/-) | 2.3 % | NA | not evaluable | | non important | - |
Sepsis TRAE (grade 3-4) | 0.97 [0.02, 49.28] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Skin exfoliation TRAE (grade 3-4) | 1.95 [0.07, 58.51] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 2.00 [0.67, 5.97] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.48 [0.02, 14.54] | | < 1 | | 0% | 1 study (1/-) | 65.9 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.32 [0.03, 3.11] | | < 1 | | 0% | 1 study (1/-) | 83.5 % | NA | not evaluable | | non important | - |